Drug intelligence / Profile preview

NS-136

Development stage: Phase 2
Lead developer: NeuShen Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

NS-136 is a novel, selective muscarinic acetylcholine M4 receptor positive allosteric modulator (M4 PAM) under development by NeuShen Therapeutics for the treatment of schizophrenia and psychosis associated with Alzheimer's disease. It is an orally administered small molecule designed using artificial intelligence-based platform technology. Preclinical studies have shown efficacy against both positive and negative symptoms of schizophrenia as well as pro-cognitive effects in animal models. As of May 2024, it is in Phase I clinical trials for schizophrenia and preclinical development for Alzheimer's disease. The drug may also have potential applications in treating psychosis related to Parkinson's disease[1][2][5][8].

Other names: NS-136NS136NS 136

Targets

CHRM4 (M4)

Beyond the preview

Go deeper on NS-136.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NS-136.

Explore the full profile